Unlocking Innovation, Technology Through Development

Sypharma is an Australian speciality contract development manufacturing group,
motivated by a commitment to creating healthier futures.

Unlocking Advantage, Possibilities Through Tax Incentives

Sypharma as an Australian speciality contract development manufacturing group,
can extend Australian R&D tax incentives to our clients.

Unlocking Speed, Agility, Commercialization Through Manufacturing

Sypharma as an Australian speciality contract development manufacturing group,
can extend Australian R&D tax incentives to our clients.

Unlocking a healthy future together

We are a globally respected CDMO motivated by a commitment to helping our partners create a healthier future.

Developing, Manufacturing & Marketing of Therapeutic Goods

We strive to go beyond what is expected, to deliver quality solutions and valuable partnerships.

Rely on us for integrated CDMO services to bring your concept to reality.

Comprehensive Pharmaceutical Development

Our team of experienced scientists are constantly looking for ways to excel and unlock innovation through collaborative intelligence, process agility and production efficiency delivering better, smarter outcomes.

Why Us

Why Us

Great Ideas &
Life Changing Products

Our service offering includes new drug development, early stage formulation and analytical development.

Following early stage development, we continue with further development, scale-up and process validation ahead of commercial launch for a variety of dosage forms, all supported by full in-house analytical development and release laboratory.

Services

Services

Sypharma is
about People

At Sypharma we aspire to lead the way, unlocking opportunities and realising the full potential in every moment and every person. This gives meaning to everything we do and it is behind our focus and dedication.

By effectively working together in close collaboration our team tap into our full potential and drive every projects success

People

People

Quality & Compliance

Our uncompromising commitment to quality and compliance begins with research and development and continues through each stage of the drug development and commercialization process.

Facilities

Facilities

Unlocking potential at every stage

Sypharma is devoted to the development of new medicines and products that provide meaningful therapeutic benefit globally. Combining our extensive knowledge on a broad range of technologies, scientific rigor and creativity, our scientists, engineers and projects leaders use their expertise to deliver innovative and effective biotech solutions that make a difference.

DISCOVERY & DEVELOPMENT
Drug discovery process

Molecule Screening
PRECLINICAL RESEARCH
Formulation development and optimization
Animal and
Toxicological Study
CLINICAL
TRIALS
Manufacture of GMP lots for clinical supply.

Phases I, II & III
REGULATORY SUBMISSION
Approval submission to regulatory authorities.
Registration and
Market Authorization
COMMERCIAL MANUFACTURING
Cost-effective production & manufacturing capability.

Commercialization

Unlocking results together

We collaborate closely with innovative biotech professionals to ensure that your journey to drug production reaches its destination successfully. Your success means the world to us, and our dedicated team of experts will provide support and guidance from the earliest stage of development through commercialization and beyond.

RESOURCE CENTRE

COVAX-19 vaccine reaches major milestone in the race for approval.
COVID-19 vaccine developed by Vaxine Pty Ltd is the first Australian vaccine to reach final Phase 2 and 3 clinical trials.
Read Case Study
COVID19 Pandemic Products – Hand Sanitisers and Disposable Masks.
As Sypharma continues to closely monitor the CoVID-19 Pandemic, our primary concern is the health and safety of our staff, customers and the community. We will continue to deliver our products and we will endeavor to maintain our supply chain at this critical time in order to minimize disruptions to our customers.
Read Case Study
Sypharma and Schott Unlocking Possibilities Together
Together SYPHARMA and SCHOTT offer value beyond superior quality. We develop products and services that
not only deliver reliability and accuracy but improve our customers’ efficiency and performance.
Read Case Study

RESOURCE CENTRE

Quality our clients and collaborators rely on

We are proud to hold accreditation across international codes of Good Manufacturing Practice (GMP) and all our goods and services are supplied under license of the Therapeutic Goods Administration (TGA), ISO13485 Medical Device and the Australian Pesticides and Veterinary Medicines Authority (APVMA).

Press releases

RESOURCE CENTRE

University of Queensland partners with Sypharma
Sypharma partners with The University of Queensland for the manufacture of their CoVID-19 Vaccine Product.
Read Press Release
Technovalia, Sypharma and BioNet announce the establishment of Genetis
Technovalia, Sypharma and BioNet announce the establishment of Genetis, the first Australian Vaccine Development and Manufacturing Hub for mRNA, DNA and recombinant vaccines.
Read Press Release
Sypharma partners with Vaxine Pty Ltd. to manufacture COVID-19 vaccine.
Sypharma partners with Vaxine Pty Ltd. to manufacture COVID-19 vaccine product.
Read Press Release
Australian startups push for bigger role in vaccine-making.
Australian startups push for bigger role in vaccine-making.
Read Press Release
CoVax19 – Merck Vaxine Sypharma Press Release.
Sypharma Partners with Vaxine — COVAX-19 Vaccine Candidate Enters Phase 1 Human Trials.
Read Press Release